45 filings · most recent first
CRNX 8-K Filings
Crinetics Pharmaceuticals Announces Merger With Vertex Pharmaceuticals
Crinetics Pharmaceuticals Annual Meeting Results
Crinetics Pharmaceuticals Reports Strong First Quarter 2026 Financial Results
Jeff Knight Resigns As Chief Development And Operating Officer
Crinetics Pharmaceuticals Announces Resignation Of Chief Development And
Crinetics Pharmaceuticals Appoints New Auditor Following Dismissal Of Bdo Usa
Crinetics Pharmaceuticals Reports Strong Financial Results And Clinical
Crinetics Pharmaceuticals Announces Internal Role Change For Chief Development
Crinetics Pharmaceuticals Announces Departure Of Chief Medical And Development
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results And
Fda Approves Crinetics Palsonify For Acromegaly Treatment
Crinetics Pharmaceuticals Reports Preliminary Q4 2025 Financial Results And
Crinetics Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Crinetics Pharmaceuticals Announces Palsonify Revenue And Positive Phase 2
Crinetics Pharmaceuticals Reports Q2 2025 Financial Results And Provides
Crinetics Pharmaceuticals Announces Coo Departure And Consulting Agreement
Crinetics Pharmaceuticals Announces Public Offering Of Common Stock
Crinetics Pharmaceuticals Announces Sales Agreement For Common Stock
Crinetics Pharmaceuticals Announces Positive Initial Findings For Atumelnant At
Crinetics Pharmaceuticals Announces Early Release Of Endo 2024 Latebreaking
Crinetics Pharmaceuticals Adopts Excess Deferral Plan
Crinetics Pharmaceuticals Announces Positive Topline Results For Paltusotine In
Crinetics Pharmaceuticals Announces Positive Topline Results From Phase 2 Study
Crinetics Pharmaceuticals Announces 350 Million Private Placement
Crinetics Pharmaceuticals Announces Key Priorities And Milestones For 2024 At
Vertex Pharmaceuticals To Acquire Crinetics Pharmaceuticals In 10 Billion Deal
Crinetics Pharmaceuticals Announces Key Presentations At Endo 2025
Crinetics Pharmaceuticals Hosts Rd Day Highlighting Preclinical Pipeline
Crinetics Pharmaceuticals Annual Meeting Voting Results
Crinetics Pharmaceuticals Reports Q1 2025 Financial Results
Crinetics Pharmaceuticals Transitions Former Cfo To Consultant Role
Crinetics Pharmaceuticals Reports 2024 Financial Results And Business Update
Crinetics Pharmaceuticals Appoints New Cfo Schilke
Crinetics Pharmaceuticals To Present At 43Rd Annual Jp Morgan Healthcare
Crinetics Pharmaceuticals Announces Positive Topline Results From Phase 2 Trial
Crinetics Pharmaceuticals Appoints Isabel Kalofonos As Chief Commercial Officer
Crinetics Pharmaceuticals Announces Fda Acceptance Of Nda For Paltusotine For
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results And
Crinetics Submits Nda For Paltusotine To Treat Acromegaly
Crinetics Pharmaceuticals Announces Departure Of Chief Commercial Officer
Crinetics Pharmaceuticals Announces Q2 2024 Financial Results And Business
Crinetics Pharmaceuticals Annual Meeting Voting Results Announced
Crinetics Pharmaceuticals Reports Q1 2024 Financial Results And Business Update
Crinetics Pharmaceuticals Announces Upcoming Presentations At Endo 2024
Crinetics Pharmaceuticals Announces Fourth Quarter 2023 Results And Private